Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children

NCT ID: NCT05818644

Last Updated: 2025-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-28

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to investigate the incidence, current management practices, and outcomes in pediatric patients with HAC after liver transplantation.

Research question:

* What are the overall incidence of HAC and the effectiveness of all treatment strategies for HAC after pediatric LT?
* What are the current management practices in the experience of centers, anticoagulant therapy, screening protocol, and assessment criteria for HAC after pediatric LT?

The burden of participation is considered to be minimal, and limited to the questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Artery Thrombosis Hepatic Artery Stenosis Pediatric ALL Liver Transplant; Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conservative treatment

No interventions assigned to this group

Surgical revascularization

No interventions assigned to this group

Endovascular revascularization

No interventions assigned to this group

Re-transplantation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver transplantation between January 1st 2002 and January 1st 2022, diagnoses of HAC after LT
* The age of the patient is below 18 years at the time of diagnosis and intervention
* The date of diagnosis of HAC or intervention was before January 1st 2023. HAC occurring after first or subsequent LTs are included.

Exclusion Criteria

N/A
Minimum Eligible Age

0 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

J. P. Garrahan Hospital

UNKNOWN

Sponsor Role collaborator

Hospital Italiano de Buenos Aires

OTHER

Sponsor Role collaborator

Royal Children's Hospital

OTHER

Sponsor Role collaborator

Medical University of Innsbruck

UNKNOWN

Sponsor Role collaborator

Hospital Sírio-Libanês

UNKNOWN

Sponsor Role collaborator

Hospital Santo Antonio

UNKNOWN

Sponsor Role collaborator

Faculty of Medicine & Dentistry, University of Alberta

UNKNOWN

Sponsor Role collaborator

Zhejiang University

OTHER

Sponsor Role collaborator

Thomayer University Hospital

OTHER

Sponsor Role collaborator

Hôpital Bicêtre

UNKNOWN

Sponsor Role collaborator

University Children's Hospital

OTHER

Sponsor Role collaborator

Hannover Medical School

OTHER

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role collaborator

Dr Rela Institute and Medical Centre

UNKNOWN

Sponsor Role collaborator

Amrita Institute of Medical Sciences & Research Centre

UNKNOWN

Sponsor Role collaborator

Max Super Speciality Hospital

OTHER

Sponsor Role collaborator

Aster CMI Hospital

UNKNOWN

Sponsor Role collaborator

ASST Papa Giovanni XXIII Hospital

UNKNOWN

Sponsor Role collaborator

Bambino Gesù Children's Hospital

UNKNOWN

Sponsor Role collaborator

National Centre for Child Health and Development

UNKNOWN

Sponsor Role collaborator

Auckland City Hospital

OTHER_GOV

Sponsor Role collaborator

Children's Memorial Health Institute

UNKNOWN

Sponsor Role collaborator

King Faisal Specialist Hospital & Research Center

OTHER

Sponsor Role collaborator

National University Hospital, Singapore

OTHER

Sponsor Role collaborator

Wits Donald Gordon Medical Centre

UNKNOWN

Sponsor Role collaborator

La Paz University Hospital

UNKNOWN

Sponsor Role collaborator

Vall d'Hebron Barcelona Hospital Campus

UNKNOWN

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role collaborator

University Hospital, Geneva

OTHER

Sponsor Role collaborator

Birmingham Women's and Children's Hospital

UNKNOWN

Sponsor Role collaborator

Primary Children's Hospital

OTHER

Sponsor Role collaborator

Children's Hospital of Philadelphia

OTHER

Sponsor Role collaborator

Children's Hospital Pittsburgh

UNKNOWN

Sponsor Role collaborator

Recanati-Miller Transplantation Institute, Mount Sinai Hospital

UNKNOWN

Sponsor Role collaborator

Ann and Robert H. Lurie Children's Hospital of Chicago

UNKNOWN

Sponsor Role collaborator

University Medical Center Groningen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Li W, van der Doef HPJ, Wildhaber BE, Marra P, Bravi M, Pinelli D, Minetto J, Dip M, Sierre S, de Santibanes M, Ardiles V, Uno JW, Hardikar W, Bates S, Goh L, Aldrian D, Seisenbacher J, Vogel GF, Neto JS, Antunes da Fonseca E, Magalhaes Costa C, Ferreira CT, Nader LS, Farina MA, Dajani KZ, Parente A, Bigam DL, Liang TB, Bai X, Zhang W, Gonsorcikova L, Fronek J, Bohus S, Franchi-Abella S, Gonzales E, Guerin F, Junge N, Baumann U, Richter N, Hartleif S, Sturm E, Rajakannu M, Palaniappan K, Rela M, Pawaria A, Rajakrishnan H, Surendran S, Kumar M, Agarwal S, Gupta S, Asthana S, Bandewar V, Raichurkar K, Spada M, Monti L, Alterio T, Yanagi Y, Uchida H, Komine R, Evans H, Carr-Boyd P, Duncan D, Stefanowicz M, Latka-Grot J, Kolesnik A, Broering DC, Raptis DA, Ann H Marquez K, Mali V, Aw M, Beretta M, Van der Schyff F, Quintero-Bernabeu J, Mercadal-Hally M, Larrarte K M, Andres AM, Hernandez-Oliveros F, Frauca E, Casswall T, Jorns C, Delle M, Gupte G, Sharif K, McGuirk S, Superina R, Caicedo JC, Jaramillo C, Bitterfeld L, Kastenberg Z, Shah AA, Domenick B, Acord MR, Mazariegos GV, Soltys K, DiNorcia J, Antala S, Florman SS, Buchholz BM, Herden U, Fischer L, Dierckx RAJO, Hartog H, Bokkers RPH. Incidence, management and outcomes in hepatic artery complications after paediatric liver transplantation: protocol of the retrospective, international, multicentre HEPATIC Registry. BMJ Open. 2024 Jun 12;14(6):e081933. doi: 10.1136/bmjopen-2023-081933.

Reference Type DERIVED
PMID: 38866577 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17033

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ultra-low-dose Chest CT for HHT
NCT04874558 ACTIVE_NOT_RECRUITING
Pediatric Vascular Trauma
NCT06840249 RECRUITING